Literature DB >> 23108303

Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma.

Fei Zhao1, Firouzeh Korangy, Tim F Greten.   

Abstract

Hepatocellular carcinoma (HCC) has been shown to induce several immune suppressor mechanisms in patients. Our laboratory has been investigating different cellular mechanisms of immune suppression in patients with HCC. These suppressor mechanisms range from CD4(+) regulatory T cells, functionally impaired dendritic cells, neutrophils, and monocytes to myeloid-derived suppressor cells. In vitro as well as in vivo studies have demonstrated that abrogation of the suppressor cells enhances or unmasks tumor-specific anti-tumor immune responses. We performed a literature search for immune suppressor cells in HCC, and here we provide a comprehensive summary of the latest studies in this field.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 23108303      PMCID: PMC3530892          DOI: 10.1159/000341695

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  49 in total

Review 1.  T(H)17 cells in tumour immunity and immunotherapy.

Authors:  Weiping Zou; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2010-04       Impact factor: 53.106

Review 2.  Immunotherapy of hepatocellular carcinoma.

Authors:  Tim F Greten; Michael P Manns; Firouzeh Korangy
Journal:  J Hepatol       Date:  2006-09-29       Impact factor: 25.083

3.  Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells.

Authors:  Bastian Hoechst; Jaba Gamrekelashvili; Michael P Manns; Tim F Greten; Firouzeh Korangy
Journal:  Blood       Date:  2011-04-14       Impact factor: 22.113

Review 4.  Immunotherapy of hepatocellular carcinoma.

Authors:  Firouzeh Korangy; Bastian Höchst; Michael P Manns; Tim F Greten
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2010-06       Impact factor: 3.869

5.  Human CCR4+ CCR6+ Th17 cells suppress autologous CD8+ T cell responses.

Authors:  Fei Zhao; Bastian Hoechst; Jaba Gamrekelashvili; Lars A Ormandy; Torsten Voigtländer; Heiner Wedemeyer; Kris Ylaya; Xin Wei Wang; Stephen M Hewitt; Michael P Manns; Firouzeh Korangy; Tim F Greten
Journal:  J Immunol       Date:  2012-05-21       Impact factor: 5.422

6.  Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients.

Authors:  Dong-Ming Kuang; Chen Peng; Qiyi Zhao; Yan Wu; Ling-Yan Zhu; Jianen Wang; Xiao-Yu Yin; Lian Li; Limin Zheng
Journal:  J Immunol       Date:  2010-06-25       Impact factor: 5.422

7.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.

Authors:  Mei-Ling Chen; Mikaël J Pittet; Leonid Gorelik; Richard A Flavell; Ralph Weissleder; Harald von Boehmer; Khashayarsha Khazaie
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-27       Impact factor: 11.205

8.  Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC.

Authors:  Tim F Greten; Lars A Ormandy; Annika Fikuart; Bastian Höchst; Sylvana Henschen; Monique Hörning; Michael P Manns; Firouzeh Korangy
Journal:  J Immunother       Date:  2010 Feb-Mar       Impact factor: 4.456

9.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

10.  X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy.

Authors:  R S Wildin; F Ramsdell; J Peake; F Faravelli; J L Casanova; N Buist; E Levy-Lahad; M Mazzella; O Goulet; L Perroni; F D Bricarelli; G Byrne; M McEuen; S Proll; M Appleby; M E Brunkow
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

View more
  14 in total

Review 1.  Hepatocellular carcinoma and the risk of occupational exposure.

Authors:  Venerando Rapisarda; Carla Loreto; Michele Malaguarnera; Annalisa Ardiri; Maria Proiti; Giuseppe Rigano; Evelise Frazzetto; Maria Irene Ruggeri; Giulia Malaguarnera; Nicoletta Bertino; Mariano Malaguarnera; Vito Emanuele Catania; Isidoro Di Carlo; Adriana Toro; Emanuele Bertino; Dario Mangano; Gaetano Bertino
Journal:  World J Hepatol       Date:  2016-05-08

2.  A different representation of natural T cells and natural killer cells between tumor-infiltrating and periphery lymphocytes in human hepatocellular carcinoma.

Authors:  Xiao-Feng Li; Dong Dai; Xiu-Yu Song; Jian-Jing Liu; Lei Zhu; Xiang Zhu; Wenchao Ma; Wengui Xu
Journal:  Oncol Lett       Date:  2017-03-06       Impact factor: 2.967

3.  Donor-derived regulatory dendritic cell infusion results in host cell cross-dressing and T cell subset changes in prospective living donor liver transplant recipients.

Authors:  Camila Macedo; Lillian M Tran; Alan F Zahorchak; Helong Dai; Xinyan Gu; Ranjithkumar Ravichandran; Thalachallour Mohanakumar; Beth Elinoff; Adriana Zeevi; Mindi A Styn; Abhinav Humar; Fadi G Lakkis; Diana M Metes; Angus W Thomson
Journal:  Am J Transplant       Date:  2020-12-23       Impact factor: 9.369

4.  Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.

Authors:  Valli De Re; Laura Caggiari; Mariangela De Zorzi; Ombretta Repetto; Anna Linda Zignego; Francesco Izzo; Maria Lina Tornesello; Franco Maria Buonaguro; Alessandra Mangia; Domenico Sansonno; Vito Racanelli; Salvatore De Vita; Pietro Pioltelli; Emanuela Vaccher; Massimiliano Berretta; Massimiliano Beretta; Cesare Mazzaro; Massimo Libra; Andrea Gini; Antonella Zucchetto; Renato Cannizzaro; Paolo De Paoli
Journal:  PLoS One       Date:  2015-02-20       Impact factor: 3.240

5.  Identification of a FOXP3(+)CD3(+)CD56(+) population with immunosuppressive function in cancer tissues of human hepatocellular carcinoma.

Authors:  Xiaofeng Li; Jirun Peng; Yanli Pang; Sen Yu; Xin Yu; Pengcheng Chen; Wenzhen Wang; Wenling Han; Jun Zhang; Yanhui Yin; Yu Zhang
Journal:  Sci Rep       Date:  2015-10-06       Impact factor: 4.379

Review 6.  The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies.

Authors:  Gaetano Bertino; Shirin Demma; Annalisa Ardiri; Maria Proiti; Alessandra Mangia; Salvatore Gruttadauria; Adriana Toro; Isidoro Di Carlo; Giulia Malaguarnera; Nicoletta Bertino; Mariano Malaguarnera; Michele Malaguarnera
Journal:  Biomed Res Int       Date:  2015-03-29       Impact factor: 3.411

7.  Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection.

Authors:  Chao He; Wei Peng; Chuan Li; Tian-Fu Wen
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

Review 8.  Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.

Authors:  Christopher Groth; Xiaoying Hu; Rebekka Weber; Viktor Fleming; Peter Altevogt; Jochen Utikal; Viktor Umansky
Journal:  Br J Cancer       Date:  2018-11-09       Impact factor: 7.640

Review 9.  Role of lymphocytes in liver cancer.

Authors:  Jana C Mossanen; Frank Tacke
Journal:  Oncoimmunology       Date:  2013-10-21       Impact factor: 8.110

Review 10.  Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.

Authors:  Gaetano Bertino; Shirin Demma; Annalisa Ardiri; Maria Proiti; Salvatore Gruttadauria; Adriana Toro; Giulia Malaguarnera; Nicoletta Bertino; Michele Malaguarnera; Mariano Malaguarnera; Isidoro Di Carlo
Journal:  Biomed Res Int       Date:  2014-06-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.